| Popis: |
Background Human papillomavirus (HPV) is the main cause of cervical cancer. HPV-vaccines have led to a significant decrease in HPV-infections and related cancer cases. The estimation of the current HPV-prevalence and distribution of different HPV-types among women with cervical dysplasia in the post-vaccination era is of great importance for the future vaccination strategy.Methods By using a multiplexed bead-based immunoassay, we revealed the prevalence of 27 HPV-types in 170 dysplasia women from Sweden, a country with high HPV-vaccination coverage.Results The prevalence of HPV in low-and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively) were 56.3% and 76.7%, respectively. The oncogenic HPV-types constituted 80.0%, and 97.1% among the HPV-positive LSIL and HSIL-groups, respectively, with HPV16 as the most prevalent type. We found a reduction in HPV-types covered by quadrivalent-Gardasil® vaccine in the vaccinated HSIL-group, suggesting the efficiency of the HPV-vaccine in preventing dysplasia caused by the covered HPV-types. Oncogenic HPV-types 39 and 59, not covered by any current vaccine have a high prevalence among patients with cervical dysplasiaConclusions Oncogenic-HPV-types are highly prevalent among women with HSIL. The current vaccine presents a high efficiency for reducing the covered HPV-types among dysplasia patients. Lastly, we provide evidence for the oncogenic-HPV-types that should be covered in the next generation of HPV-vaccines. |
